Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor-and HER2-defined subtypes

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 384-391

  Masuda, H ^a   Brewer, T M ^a   Liu, D D ^a   Iwamoto, T ^a   Shen, Y ^a   Hsu, L ^a   Willey, J S ^a   Gonzalez Angulo, A M ^a   Chavez MacGregor, M ^a   Fouad, T M ^a   Woodward, W A ^a   Reuben, J M ^a   Valero, V ^a   Alvarez, R H ^a   Hortobagyi, G N ^a   Ueno, N T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast neoplasm; HER2; Hormonal receptor; Inflammatory breast cancer; Prognosis factor; Subtype

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TAXOID;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HR NEGATIVE HER2 POSITIVE BREAST CANCER SUBTYPE; HR POSITIVE HER2 NEGATIVE BREAST CANCER SUBTYPE; HUMAN; INFLAMMATORY BREAST CANCER; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; INFLAMMATORY BREAST NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TAXOIDS; TRASTUZUMAB; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84893405141     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt525     Document Type: Article

References (15)

1. Dawood S, Merajver SD, Viens P et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011; 22: 515-523.
2. Hance KW, Anderson WF, Devesa SS et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97: 966-975.
3. Schlichting JA, Soliman AS, Schairer C et al. Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008. Breast Cancer Res Treat 2012; 134: 1257-1268.
4. Dawood S, Ueno NT, Valero V et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 2011; 117: 1819-1826.
5. Li J, Gonzalez-Angulo AM, Allen PK et al. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 2011; 16: 1675-1683.
6. Gonzalez-Angulo AM, Hennessy BT, Broglio K et al. Trends for inflammatory breast cancer: is survival improving? Oncologist 2007; 12: 904-912.
7. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
8. Panades M, Olivotto IA, Speers CH et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 2005; 23: 1941-1950.
9. Costa SD, Loibl S, Kaufmann M et al. Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol 2010; 28: 83-91.
10. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
11. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
12. Knight WA, Livingston RB, Gregory EJ et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37: 4669-4671.
13. Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol 2009; 19: 204-210.
14. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
15. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.